Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
Safety and Risk of Pharmacotherapy
doi 10.30895/2312-7821-2020-8-1-9-22
Full Text
Open PDFAbstract
Available in full text
Date
March 26, 2020
Authors
Publisher
SCEEMP